You are using an older browser version. Please use a supported version for the best MSN experience.

Biogen halts trial of its Alzheimer’s drug Aducanumab

Biogen decided to end its phase 3 trial of its Alzheimer’s drug Aducanumab. Heritage Capital LLC President Paul Schatz and Yahoo Finance’s Brian Sozzi, Scott Gamm and Alexis Christoforous break down the impact on the company.

Latest

Sport

Business

Editor's Picks

World

Featured Partners

image beaconimage beaconimage beacon